Key takeaways
- Piper Sandler upgraded Medtronic (NYSE: MDT) to Overweight with a $120 price target.
- Medtronic is expanding its medical technology portfolio through strategic acquisitions and product launches in vascular, heart rhythm, and robotic surgery.
- The company's Symplicity Spyral renal denervation treatment received CMS coverage, opening access to over 18 million U.S. patients.
Medtronic (NYSE: MDT) develops medical technologies for vascular disease, heart rhythm, and surgery. Piper Sandler upgraded Medtronic to Overweight when shares were trading at $102.88. Its $120 price target was 16.64% above that price.
Medtronic plans to acquire privately held Contego Medical, expanding its portfolio of carotid technologies and therapies for peripheral vascular disease. The deal builds on an exclusive U.S. distribution agreement announced in January 2025. Medtronic executive David Moeller says the acquisition strengthens its position in treating carotid artery disease.
Affera and PulseSelect are expanding Medtronic’s heart-rhythm business and driving material revenue growth and opportunities for recurring procedure sales. CMS coverage for its Symplicity Spyral renal denervation treatment removes a commercial barrier and enables access to more than 18 million target U.S. patients with hypertension.
Medtronic’s Hugo robotic surgery platform has received initial U.S. clearance for urologic procedures, with future growth tied to more instruments and procedure approvals. Shares were at $102.88, up $0.02, or 0.02%, and traded between $102.85 and $104.49 during the day.
Medtronic’s 52-week range was $73.31 to $106.33. Its market capitalization was $131.6 billion, and trading volume was 6.73 million shares.
